PPD Named Clinical Research Company of the Year for Second Consecutive Year


WILMINGTON, NC–(BUSINESS WIRE)–PPD, Inc. (Nasdaq: PPD) has been named Clinical Research Company of the Year at the 2021 PharmaTimes Clinical Researcher of the Year international competition in London.

In addition to PPD winning the highest honor, individual PPD Clinical Investigators won Gold and Silver in the Clinical Research Team and Start Up-Singles categories, as well as Silver and Bronze awards in the Aspiring Clinical Research Associate (CRA) category and bronze in the internal ARC category.

“This is the second year in a row that PPD has won this award, and we are thrilled that our clinical investigators continue to be recognized by PharmaTimes for their talent, work ethic and commitment to this industry year after year,” said Amber Lee, senior vice president of clinical operations for PPD. “Our clinical research professionals are key to our clients’ success as they help advance safe and effective treatment options through clinical trials.”

This recognition demonstrates the high caliber of PPD’s clinical research professionals and the effectiveness of PPD’s award-winning training and development programs, such as the company’s Clinical Foundations Program and its CRA Academy. These programs help prepare and equip research professionals to deliver high performance, quality and value to PPD customers.

The Clinical Investigator of the Year awards are the culmination of a series of rigorous judging, including a three-stage competition culminating in presentations to a panel of industry-experienced judges. The event was created to provide clinical research professionals with the opportunity to benchmark their professional skills against those of their peers through a program of competency-based exercises developed through cross-industry collaboration.

About PDP

PPD is a leading global contract research organization that provides comprehensive and integrated drug development, laboratory and lifecycle management services. Our customers and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With over 30,000 professionals worldwide, PPD has conducted clinical trials in over 100 countries to help customers deliver life-changing therapies to improve health. We apply innovative technologies, therapeutic expertise and a strong commitment to quality to bend the cost and time curve of drug development and maximize value. For more information, visit www.ppd.com.

This press release contains forward-looking statements. These statements often include words such as “expect”, “believe”, “project”, “anticipate”, “estimate”, “target” and other similar expressions. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results and, therefore, actual results could differ materially from those expressed in forward-looking statements. . Factors that could materially affect these forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changing trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; risks related to the proposed merger of PPD by Thermo Fisher Scientific Inc.; and other factors disclosed in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission (SEC), including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q , which are available on our website at https://investors.ppd.com or the SEC’s website at www.sec.gov. We undertake no obligation and disclaim any obligation to revise or update any forward-looking statements, or to make new forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. applicable so requires.


Comments are closed.